Ticker Details
TG Therapeutics, Inc. TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development & commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
IPO Date:	June 1, 2010
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$4.69B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.46 | 3.12%
Avg Daily Range (30 D):	$0.61 | 2.04%
Avg Daily Range (90 D):	$0.60 | 1.91%

Institutional Daily Volume
Avg Daily Volume:	1.66M
Avg Daily Volume (30 D):	1.69M
Avg Daily Volume (90 D):	1.54M

Trade Size
Avg Trade Size (Sh.):	116
Avg Trade Size (Sh.) (30 D):	73
Avg Trade Size (Sh.) (90 D):	68

Institutional Trades
Total Institutional Trades:	5,850
Avg Institutional Trade:	$2.86M
Avg Institutional Trade (30 D):	$3.33M
Avg Institutional Trade (90 D):	$3.57M
Avg Institutional Trade Volume:	.15M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$5.08M
Avg Closing Trade (30 D):	$7.34M
Avg Closing Trade (90 D):	$8.04M
Avg Closing Volume:	263.26K

News

Feb 8, 2026 @ 9:17 PM TG Therapeutics Announces Collaboration with Chris... Source: Tg Therapeutics, Inc.

Jan 14, 2026 @ 1:36 PM Stock Market Today: S&P 500, Dow Jones, Nasdaq 100... Source: Rishabh Mishra

Nov 10, 2025 @ 9:00 PM TG Therapeutics to Participate in the TD Cowen Imm... Source: Tg Therapeutics, Inc.

Aug 4, 2025 @ 4:23 PM TG Therapeutics Q2 Revenue Up 91% Source: Jesterai

May 5, 2025 @ 11:00 AM TG Therapeutics Reports First Quarter 2025 Financi... Source: N/A

Financials
	TTM	Q2 2025	Q1 2025
Basic EPS	$2.69	$.19	$.03
Diluted EPS	$2.43	$.17	$.03
Revenue	$161.71M	$141.15M	$120.86M
Gross Profit	$133.62M	$122.21M	$105.32M
Net Income / Loss	$390.9M	$28.19M	$5.06M
Operating Income / Loss	$29.37M	$34.84M	$8.62M
Cost of Revenue	$28.09M	$18.94M	$15.54M
Net Cash Flow	$-55.03M	$-3M	$-47.75M
PE Ratio	12.48

Splits
Apr 30, 2012	5:281
Jul 14, 2011	1:50
Sep 25, 2003	1:5